Effect of the C3a-Receptor Antagonist SB 290157 on Anti-OVA Polyclonal Antibody-Induced Arthritis
It was investigated whether the C3a-receptor antagonist (C3aRA) SB 290157 was involved in the suppression of anti-OVA pAb-induced arthritis because it is well known that anaphylatoxin C3a plays a crucial role in the development of an effective inflammatory response during complement activation. Anti...
Saved in:
Main Authors: | Pilaiwanwadee Hutamekalin (Author), Kohei Takeda (Author), Mitsuhiro Tani (Author), Yuko Tsuga (Author), Naoki Ogawa (Author), Nobuaki Mizutani (Author), Shin Yoshino (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2010-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The "C3aR Antagonist" SB290157 is a Partial C5aR2 Agonist
by: Xaria X. Li, et al.
Published: (2021) -
Arthrogenicity of type II collagen monoclonal antibodies associated with complement activation and antigen affinity
by: Mizutani Nobuaki, et al.
Published: (2011) -
Polyclonal antibodies for the detection of Trypanosoma cruzi circulating antigens.
by: Edith S Málaga-Machaca, et al.
Published: (2017) -
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
by: Evi B. Struble, et al.
Published: (2023) -
Antibody immunoprophylaxis and immunotherapy for influenza virus infection: Utilization of monoclonal or polyclonal antibodies?
by: Cassandra M. Berry
Published: (2018)